Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV), formally designated the human herpesvirus 8 (HHV-8), is the causative agent of Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and plasmablastic variant of multicentric Castleman’s disease (MCD). KSHV also has been linked to another pathological condition with many features in common with MCD, named KSHV inflammatory cytokine syndrome (KICS) and with a number of other rare lymphoproliferative conditions. KSHV infection is highly prevalent in sub-Saharan Africa and among some Amerindian and Melanesian populations, and diffuse in the Mediterranean area and in parts of South America. KSHV is less prevalent in Northern Europe, North America, and most of Asia. KSHV is transmitted via nonsexual routes during childhood in regions with intermediate and high seroprevalence, and mainly via sexual contact during adulthood in countries with low seroprevalence. Saliva is an important reservoir of infectious virus and plays a central role in both sexual and nonsexual modalities of transmission. KSHV is equipped with unique and host-pirated gene products with oncogenic properties and ability to increase the survival and proliferation of infected cells, modulate cellular transcriptome, alter cellular epigenetic, and induce genetic instability. KSHV encodes a set of noncoding RNAs, including micro, long noncoding, and circular RNAs that provide alternative strategies to modulate host gene expression while avoiding recognition by the host immune system. In vitro studies, animal models, and recombinant viruses have greatly increased our knowledge of the KSHV-driven pathogenic mechanisms. A distinctive characteristic of KSHV pathogenesis is that viral genes expressed during the lytic infection cycle generate an inflammatory microenvironment that cooperates with latent viral gene products in cell immortalization and transformation. Several aspects of KSHV-induced pathogenesis and many of the predisposing factors remain to be revealed, and only a small part of the new findings has been translated into an effective clinical practice. Globally useful or population-based prognostic and predictive biomarkers for KSHV-related disorders still need to be defined to guide physicians in the choice of therapeutic strategies and to selectively monitor patients at risk.
This is a preview of subscription content, log in via an institution to check access.
References
Aavikko M, Kaasinen E, Nieminen JK, Byun M, Donner I, Mancuso R, et al. Whole-genome sequencing identifies STAT4 as a putative susceptibility gene in classic Kaposi sarcoma. J Infect Dis. 2015;211(11):1842–51.
Ablashi D, Chatlynne L, Cooper H, Thomas D, Yadav M, Norhanom AW, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer. 1999;81(5):893–7.
Ahmad A, Groshong JS, Matta H, Schamus S, Punj V, Robinson LJ, et al. Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol Ther. 2010;10(10):1033–40.
Akula SM, Wang FZ, Vieira J, Chandran B. Human herpesvirus 8 interaction with target cells involves heparan sulfate. Virology. 2001;282(2):245–55.
Alkharsah KR, Alzahrani AJ, Obeid OE, El-Harith EH, Guella A, Mohamed EA, et al. Vascular endothelial growth factor A polymorphism and risk of Kaposi’s sarcoma herpesvirus viremia in kidney allograft recipients. Transpl Infect Dis. 2014;16(5):783–9.
Alzahrani AJ, Harith e E, Milzer J, Obeid OE, Stuhrmann M, Al Dayel A, et al. Increased seroprevalence of human herpes virus-8 in renal transplant recipients in Saudi Arabia. Nephrol Dial Transplant. 2005;20(11):2532–6.
Amir H, Kaaya EE, Manji KP, Kwesigabo G, Biberfeld P. Kaposi’s sarcoma before and during a human immunodeficiency virus epidemic in Tanzanian children. Pediatr Infect Dis J. 2001;20(5):518–21.
An FQ, Compitello N, Horwitz E, Sramkoski M, Knudsen ES, Renne R. The latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J Biol Chem. 2005;280(5):3862–74.
Andrei G, Snoeck R. Kaposi’s sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy. Curr Opin Infect Dis. 2015;28(6):611–24.
Andreoni M, El-Sawaf G, Rezza G, Ensoli B, Nicastri E, Ventura L, et al. High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. J Natl Cancer Inst. 1999;91(5):465–9.
Andreoni M, Goletti D, Pezzotti P, Pozzetto A, Monini P, Sarmati L, et al. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi’s sarcoma in renal and liver transplant recipients. J Infect. 2001;43(3):195–9.
Angeloni A, Heston L, Uccini S, Sirianni MC, Cottoni F, Masala MV, et al. High prevalence of antibodies to human herpesvirus 8 in relatives of patients with classic Kaposi’s sarcoma from Sardinia. J Infect Dis. 1998;177(6):1715–8.
Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood. 1999;94(12):4247–54.
Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93(12):4034–43.
Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, et al. KSHV 2.0: a comprehensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog. 2014;10(1):e1003847.
Ariyoshi K, Schim vdL, Cook P, Whitby D, Corrah T, Jaffar S, et al. Kaposi’s sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol. 1998;1(3):193–9.
Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature. 1997;385(6614):347–50.
Ascoli V, Calabro ML, Giannakakis K, Barbierato M, Chieco-Bianchi L, Gastaldi R, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8-associated polyclonal body cavity effusions that mimic primary effusion lymphomas. Int J Cancer. 2006;119(7):1746–8. author reply 9–50
Atkinson J, Edlin BR, Engels EA, Kral AH, Seal K, Gamache CJ, et al. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis. 2003;187(6):974–81.
Austgen K, Oakes SA, Ganem D. Multiple defects, including premature apoptosis, prevent Kaposi’s sarcoma-associated herpesvirus replication in murine cells. J Virol. 2012;86(3):1877–82.
Baeten JM, Chohan BH, Lavreys L, Rakwar JP, Ashley R, Richardson BA, et al. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. AIDS. 2002;16(15):2073–8.
Balachandra B, Tunitsky E, Dawood S, Hings I, Marcus VA. Classic Kaposi’s sarcoma presenting first with gastrointestinal tract involvement in a HIV-negative Inuit male–a case report and review of the literature. Pathol Res Pract. 2006;202(8):623–6.
Ballestas ME, Kaye KM. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol. 2001;75(7):3250–8.
Ballestas ME, Kaye KM. The latency-associated nuclear antigen, a multifunctional protein central to Kaposi’s sarcoma-associated herpesvirus latency. Future Microbiol. 2011;6(12):1399–413.
Barasa AK, Ye P, Phelps M, Arivudainambi GT, Tison T, Ogembo JG. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV. Oncotarget. 2017;8(21):34481–97.
Barozzi P, Luppi M, Facchetti F, Mecucci C, Alu M, Sarid R, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med. 2003;9(5):554–61.
Barozzi P, Bonini C, Potenza L, Masetti M, Cappelli G, Gruarin P, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation. 2008;86(5):738–44.
Bechtel JT, Liang Y, Hvidding J, Ganem D. Host range of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol. 2003;77(11):6474–81.
Bechtel JT, Winant RC, Ganem D. Host and viral proteins in the virion of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2005;79(8):4952–64.
Bellare P, Ganem D. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe. 2009;6(6):570–5.
Benelli R, Albini A, Parravicini C, Carlone S, Repetto L, Tambussi G, et al. Isolation of spindle-shaped cell populations from primary cultures of Kaposi’s sarcoma of different stage. Cancer Lett. 1996;100(1–2):125–32.
Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335(8682):123–8.
Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103(11):4368–9. author reply 9
Bergson S, Kalt I, Itzhak I, Brulois KF, Jung JU, Sarid R. Fluorescent tagging and cellular distribution of the Kaposi’s sarcoma-associated herpesvirus ORF45 tegument protein. J Virol. 2014;88(21):12839–52.
Bhavsar T, Lee JC, Perner Y, Raffeld M, Xi L, Pittaluga S, et al. KSHV-associated and EBV-associated germinotropic lymphoproliferative disorder: new findings and review of the literature. Am J Surg Pathol. 2017;41(6):795–800.
Biggar RJ, Horm J, Fraumeni JF Jr, Greene MH, Goedert JJ. Incidence of Kaposi’s sarcoma and mycosis fungoides in the United States including Puerto Rico, 1973–81. J Natl Cancer Inst. 1984;73(1):89–94.
Biggar RJ, Whitby D, Marshall V, Linhares AC, Black F. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis. 2000;181(5):1562–8.
Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, Study HACM. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99(12):962–72.
Bigoni B, Dolcetti R, de Lellis L, Carbone A, Boiocchi M, Cassai E, et al. Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS. J Infect Dis. 1996;173(3):542–9.
Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, et al. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. AIDS. 2007;21(10):1245–52.
Biryahwaho B, Dollard SC, Pfeiffer RM, Shebl FM, Munuo S, Amin MM, et al. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. J Infect Dis. 2010;202(9):1347–53.
Blackbourn DJ, Osmond D, Levy JA, Lennette ET. Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. J Infect Dis. 1999;179(1):237–9.
Blackbourn DJ, Fujimura S, Kutzkey T, Levy JA. Induction of human herpesvirus-8 gene expression by recombinant interferon gamma. AIDS. 2000;14(1):98–9.
Blumenthal MJ, Schutz C, Meintjes G, Mohamed Z, Mendelson M, Ambler JM, et al. EPHA2 sequence variants are associated with susceptibility to Kaposi’s sarcoma-associated herpesvirus infection and Kaposi’s sarcoma prevalence in HIV-infected patients. Cancer Epidemiol. 2018;56:133–9.
Blumenthal MJ, Cornejo Castro EM, Whitby D, Katz AA, Schafer G. Evidence for altered host genetic factors in KSHV infection and KSHV-related disease development. Rev Med Virol. 2020:31(2):e2160.
Borst EM, Hahn G, Koszinowski UH, Messerle M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol. 1999;73(10):8320–9.
Boshoff C, Talbot S, Kennedy M, O’Leary J, Schulz T, Chang Y. HHV8 and skin cancers in immunosuppressed patients. Lancet. 1996;348(9020):138.
Boshoff C, Gao SJ, Healy LE, Matthews S, Thomas AJ, Coignet L, et al. Establishing a KSHV + cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood. 1998;91(5):1671–9.
Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372–80.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol. 2009;10(4):321–2.
Braun M. Classics in oncology. Idiopathic multiple pigmented sarcoma of the skin by Kaposi. CA Cancer J Clin. 1982;32(6):340–7.
Brayfield BP, Phiri S, Kankasa C, Muyanga J, Mantina H, Kwenda G, et al. Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection in mothers and infants from Zambia. J Infect Dis. 2003;187(4):559–68.
Brayfield BP, Kankasa C, West JT, Muyanga J, Bhat G, Klaskala W, et al. Distribution of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: implications for transmission. J Infect Dis. 2004;189(12):2260–70.
Broussard G, Damania B. Regulation of KSHV latency and lytic reactivation. Viruses. 2020;12(9):1034. https://doi.org/10.3390/v12091034.
Brown EE, Fallin D, Ruczinski I, Hutchinson A, Staats B, Vitale F, et al. Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomark Prev. 2006a;15(5):926–34.
Brown EE, Whitby D, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer. 2006b;107(9):2282–90.
Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, et al. Construction and manipulation of a new Kaposi’s sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol. 2012;86(18):9708–20.
Burbelo PD, Leahy HP, Groot S, Bishop LR, Miley W, Iadarola MJ, et al. Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection. Clin Vaccine Immunol. 2009;16(5):621–7.
Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis. 2009;200(3):430–8.
Butler LM, Were WA, Balinandi S, Downing R, Dollard S, Neilands TB, et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis. 2011;203(5):625–34.
Cai X, Cullen BR. Transcriptional origin of Kaposi’s sarcoma-associated herpesvirus microRNAs. J Virol. 2006;80(5):2234–42.
Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2006;2(10):e116.
Cai Q, Verma SC, Lu J, Robertson ES. Molecular biology of Kaposi’s sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res. 2010;78:87–142.
Calabro ML, Sarid R. Human herpesvirus 8 and lymphoproliferative disorders. Mediterr J Hematol Infect Dis. 2018;10(1):e2018061.
Calabro ML, Sheldon J, Favero A, Simpson GR, Fiore JR, Gomes E, et al. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J Hum Virol. 1998;1(3):207–13.
Calabro ML, Fiore JR, Favero A, Lepera A, Saracino A, Angarano G, et al. Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. J Infect Dis. 1999;179(6):1534–7.
Calabro ML, Gasperini P, Barbierato M, Ometto L, Zanchetta M, De Rossi A, et al. A search for human herpesvirus 8 (HHV-8) in HIV-1 infected mothers and their infants does not suggest vertical transmission of HHV-8. Int J Cancer. 2000;85(2):296–7.
Calabro ML, Gasperini P, Fiore JR, Barbierato M, Angarano G, Chieco-Bianchi L. Intrafamilial transmission of human herpesvirus 8. J Natl Cancer Inst. 2001;93(2):154–6.
Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi’s sarcoma clinical stage. AIDS. 2000;14(14):2109–16.
Cannon MJ, Dollard SC, Smith DK, Klein RS, Schuman P, Rich JD, et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med. 2001;344(9):637–43.
Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213–24.
Carroll PA, Brazeau E, Lagunoff M. Kaposi’s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology. 2004;328(1):7–18.
Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103(5):1632–4.
Cassar O, Blondot ML, Mohanna S, Jouvion G, Bravo F, Maco V, et al. Human herpesvirus 8 genotype E in patients with Kaposi sarcoma, Peru. Emerg Infect Dis. 2010;16(9):1459–62.
Cassar O, Charavay F, Bassot S, Plancoulaine S, Grangeon JP, Laumond-Barny S, et al. Divergent KSHV/HHV-8 subtype D strains in New Caledonia and Solomon Islands, Melanesia. J Clin Virol. 2012;53(3):214–8.
Caterino-de-Araujo A. Human herpesvirus 8 group B and C variants circulating in Sao Paulo, Brazil [letter]. J Infect Dis. 1998;177(4):1136–7.
Caterino-de-Araujo A, Magri MC, Manuel RC. Patterns of antibodies against latent and lytic antigens of human herpesvirus 8 in an endemic population and patients with Kaposi’s sarcoma in Mozambique. J Med Virol. 2010;82(9):1576–81.
Cathomas G, Tamm M, McGandy CE, Perruchoud AP, Mihatsch MJ, Dalquen P. Detection of herpesvirus-like DNA in the bronchoalveolar lavage fluid of patients with pulmonary Kaposi’s sarcoma. Eur Respir J. 1996;9(8):1743–6.
Cattani P, Cerimele F, Porta D, Graffeo R, Ranno S, Marchetti S, et al. Age-specific seroprevalence of human herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect. 2003;9(4):274–9.
Cattelan A, Calabro M, Gasperini P, Aversa S, Zanchetta M, Meneghetti F, et al. Acquired immunodeficiency syndrome-related Kaposi’s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr. 2001;28:44–9.
Cattelan AM, Calabro ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M, et al. Long-term clinical outcome of AIDS-related Kaposi’s sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27(3):779–85.
Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 2011;305(2):163–74.
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186–91.
Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma. J Virol. 1996;70(11):8218–23.
Chadburn A, Said J, Gratzinger D, Chan JK, de Jong D, Jaffe ES, et al. HHV8/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH/EAHP workshop report-part 3. Am J Clin Pathol. 2017;147(2):171–87.
Chakraborty S, Veettil MV, Chandran B. Kaposi’s sarcoma associated herpesvirus entry into target cells. Front Microbiol. 2012;3:6.
Challine D, Roudot-Thoraval F, Sarah T, Laperche L, Boisson B, Mauberquez S, et al. Seroprevalence of human herpes virus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses. Transfusion. 2001;41(9):1120–5.
Chandriani S, Xu Y, Ganem D. The lytic transcriptome of Kaposi’s sarcoma-associated herpesvirus reveals extensive transcription of noncoding regions, including regions antisense to important genes. J Virol. 2010;84(16):7934–42.
Chang HH, Ganem D. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe. 2013;13(4):429–40.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865–9.
Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, Godden K, et al. Cyclin encoded by KS herpesvirus [letter]. Nature. 1996;382(6590):410.
Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi’s sarcoma-associated herpesvirus lytic replication. Virology. 2000;266(1):17–25.
Chang PJ, Shedd D, Gradoville L, Cho MS, Chen LW, Chang J, et al. Open reading frame 50 protein of Kaposi’s sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J Virol. 2002;76(7):3168–78.
Chang H, Wachtman LM, Pearson CB, Lee JS, Lee HR, Lee SH, et al. Non-human primate model of Kaposi’s sarcoma-associated herpesvirus infection. PLoS Pathog. 2009;5(10):e1000606.
Chang TY, Wu YH, Cheng CC, Wang HW. Differentially regulated splice variants and systems biology analysis of Kaposi’s sarcoma-associated herpesvirus-infected lymphatic endothelial cells. Nucleic Acids Res. 2011;39(16):6970–85.
Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science. 2002;298(5597):1432–5.
Chen J, Ueda K, Sakakibara S, Okuno T, Parravicini C, Corbellino M, et al. Activation of latent Kaposi’s sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A. 2001;98(7):4119–24.
Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP. Distinct p53, p53:LANA, and LANA complexes in Kaposi’s sarcoma – associated herpesvirus lymphomas. J Virol. 2010;84(8):3898–908.
Chen J, Dai L, Barrett L, Post SR, Qin Z. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. bioRxiv. 2020;
Chironna M, Tosatti MA, Di Gangi IM, Sallustio A, Germinario C, Coluzzi M, et al. High human herpesvirus 8 seroprevalence in populations from Western Balkan countries. J Med Virol. 2006;78(7):933–7.
Chugh PE, Sin SH, Ozgur S, Henry DH, Menezes P, Griffith J, et al. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog. 2013;9(7):e1003484.
Ciufo DM, Cannon JS, Poole LJ, Wu FY, Murray P, Ambinder RF, et al. Spindle cell conversion by Kaposi’s sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol. 2001;75(12):5614–26.
Cohen A, Wolf DG, Guttman-Yassky E, Sarid R. Kaposi’s sarcoma-associated herpesvirus: clinical, diagnostic, and epidemiological aspects. Crit Rev Clin Lab Sci. 2005;42(2):101–53.
Coluzzi M, Calabro ML, Manno D, Chieco-Bianchi L, Schulz TF, Ascoli V. Saliva and the transmission of human herpesvirus 8: potential role of promoter-arthropod bites. J Infect Dis. 2004;190(1):199–200.
Concato C, Diociaiuti A, Parisi F, Giraldi L, Ciasulli A, Menichella D, et al. Human herpesvirus-8 serology in pediatric organ transplantation. Transplant Proc. 2008;40(10):3683–4.
Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi’s sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998;78(11):1521–8.
Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98(12):3473–5.
Coscoy L. Immune evasion by Kaposi’s sarcoma-associated herpesvirus. Nat Rev Immunol. 2007;7(5):391–401.
Cotter MA, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi’s sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology. 1999;264(2):254–64.
Courville EL, Sohani AR, Hasserjian RP, Zukerberg LR, Harris NL, Ferry JA. Diverse clinicopathologic features in human herpesvirus 8-associated lymphomas lead to diagnostic problems. Am J Clin Pathol. 2014;142(6):816–29.
Dai X, Gong D, Wu TT, Sun R, Zhou ZH. Organization of capsid-associated tegument components in Kaposi’s sarcoma-associated herpesvirus. J Virol. 2014;88(21):12694–702.
Dai X, Gong D, Xiao Y, Wu TT, Sun R, Zhou ZH. CryoEM and mutagenesis reveal that the smallest capsid protein cements and stabilizes Kaposi’s sarcoma-associated herpesvirus capsid. Proc Natl Acad Sci U S A. 2015;112(7):E649–56.
Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352(13):1371–3.
Davidovici B, Karakis I, Bourboulia D, Ariad S, Zong JC, Benharroch D, et al. Seroepidemiology and molecular epidemiology of Kaposi’s sarcoma-associated herpesvirus among Jewish Population Groups in Israel. J Natl Cancer Inst. 2001;93(3):194–202.
Davis MA, Sturzl MA, Blasig C, Schreier A, Guo HG, Reitz M, et al. Expression of human herpesvirus 8-encoded cyclin D in Kaposi’s sarcoma spindle cells. J Natl Cancer Inst. 1997a;89(24):1868–74.
Davis DA, Humphrey RW, Newcomb FM, O’Brien TR, Goedert JJ, Straus SE, et al. Detection of serum antibodies to a Kaposi’s sarcoma-associated herpesvirus-specific peptide. J Infect Dis. 1997b;175(5):1071–9.
Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, Tosato G, et al. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood. 2001;97(10):3244–50.
De Leo A, Deng Z, Vladimirova O, Chen HS, Dheekollu J, Calderon A, et al. LANA oligomeric architecture is essential for KSHV nuclear body formation and viral genome maintenance during latency. PLoS Pathog. 2019;15(1):e1007489.
de Sanjose S, Marshall V, Sola J, Palacio V, Almirall R, Goedert JJ, et al. Prevalence of Kaposi’s sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. Int J Cancer. 2002;98(1):155–8.
de Sanjose S, Mbisa G, Perez-Alvarez S, Benavente Y, Sukvirach S, Hieu NT, et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis. 2009;199(10):1449–56.
de Souza VA, Pierrotti LC, Sumita LM, Freire WS, Segurado AA, Pannuti CS. Seroreactivity to Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi’s sarcoma patients depends on CD4+ T-cell count. J Med Virol. 2007;79(10):1562–8.
Dedicoat M, Newton R. Review of the distribution of Kaposi’s sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi’s sarcoma. Br J Cancer. 2003;88(1):1–3.
Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B, et al. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis. 2004;190(6):1068–75.
Deng B, O’Connor CM, Kedes DH, Zhou ZH. Cryo-electron tomography of Kaposi’s sarcoma-associated herpesvirus capsids reveals dynamic scaffolding structures essential to capsid assembly and maturation. J Struct Biol. 2008;161(3):419–27.
Denis D, Seta V, Regnier-Rosencher E, Kramkimel N, Chanal J, Avril MF, et al. A fifth subtype of Kaposi’s sarcoma, classic Kaposi’s sarcoma in men who have sex with men: a cohort study in Paris. J Eur Acad Dermatol Venereol. 2018;32(8):1377–84.
DeSantis SM, Pau CP, Archibald LK, Nwanyanwu OC, Kazembe PN, Dobbie H, et al. Demographic and immune correlates of human herpesvirus 8 seropositivity in Malawi, Africa. Int J Infect Dis. 2002;6(4):266–71.
Desrosiers RC, Sasseville VG, Czajak SC, Zhang X, Mansfield KG, Kaur A, et al. A herpesvirus of rhesus monkeys related to the human Kaposi’s sarcoma- associated herpesvirus. J Virol. 1997;71(12):9764–9.
Di Bartolo DL, Cannon M, Liu YF, Renne R, Chadburn A, Boshoff C, et al. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood. 2008;111(9):4731–40.
Di Stefano M, Calabro ML, Di Gangi IM, Cantatore S, Barbierato M, Bergamo E, et al. In vitro and in vivo human herpesvirus 8 infection of placenta. PLoS One. 2008;3(12):e4073.
Dilnur P, Katano H, Wang ZH, Osakabe Y, Kudo M, Sata T, et al. Classic type of Kaposi’s sarcoma and human herpesvirus 8 infection in Xinjiang, China. Pathol Int. 2001;51(11):845–52.
DiMaio TA, Vogt DT, Lagunoff M. KSHV requires vCyclin to overcome replicative senescence in primary human lymphatic endothelial cells. PLoS Pathog. 2020;16(6):e1008634.
Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D. A cluster of latently expressed genes in Kaposi’s sarcoma-associated herpesvirus. J Virol. 1998;72(10):8309–15.
Dittmer DP, Gonzalez CM, Vahrson W, DeWire SM, Hines-Boykin R, Damania B. Whole-genome transcription profiling of rhesus monkey rhadinovirus. J Virol. 2005;79(13):8637–50.
Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999;190(7):1025–32.
Dollard SC, Nelson KE, Ness PM, Stambolis V, Kuehnert MJ, Pellett PE, et al. Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort. Transfusion. 2005;45(4):500–3.
Dollard SC, Butler LM, Jones AM, Mermin JH, Chidzonga M, Chipato T, et al. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the “Kaposi’s sarcoma belt”. Int J Cancer. 2010;127(10):2395–401.
Dollery SJ. Towards understanding KSHV fusion and entry. Viruses. 2019;11(11):1073. https://doi.org/10.3390/v11111073.
Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, Dupin N, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97(7):2130–6.
Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, Cabecadas J, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood. 2002;100(9):3415–8.
Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60(12):1350–7.
Dunn-Kittenplon DD, Kalt I, Lellouche JM, Sarid R. The KSHV portal protein ORF43 is essential for the production of infectious viral particles. Virology. 2019;529:205–15.
Dupin N, Marcelin AG, Gorin I, Bossi P, Franck N, Weill B, et al. Prevalence of human herpesvirus 8 infection measured by antibodies to a latent nuclear antigen in patients with various dermatologic diseases. Arch Dermatol. 1998;134(6):700–2.
Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96(8):4546–51.
Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406–12.
Earnshaw WC, Sullivan KF, Machlin PS, Cooke CA, Kaiser DA, Pollard TD, et al. Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen. J Cell Biol. 1987;104(4):817–29.
El-Mallawany NK, Villiera J, Kamiyango W, Peckham-Gregory EC, Scheurer ME, Allen CE, et al. Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agent Cancer. 2018;13:33.
Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, Biggar RJ. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. AIDS. 2002;16(18):2473–8.
Enbom M, Tolfvenstam T, Ghebrekidan H, Ruden U, Grandien M, Wahren B, et al. Seroprevalence of human herpes virus 8 in different Eritrean population groups. J Clin Virol. 1999;14(3):167–72.
Enbom M, Urassa W, Massambu C, Thorstensson R, Mhalu F, Linde A. Detection of human herpesvirus 8 DNA in serum from blood donors with HHV-8 antibodies indicates possible bloodborne virus transmission. J Med Virol. 2002;68(2):264–7.
Engels EA, Eastman H, Ablashi DV, Wilks RJ, Braham J, Manns A. Risk of transfusion-associated transmission of human herpesvirus 8. J Natl Cancer Inst. 1999;91(20):1773–5.
Engels EA, Sinclair MD, Biggar RJ, Whitby D, Ebbesen P, Goedert JJ, et al. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. Int J Cancer. 2000;88(6):1003–8.
Engels EA, Biggar RJ, Marshall VA, Walters MA, Gamache CJ, Whitby D, et al. Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS. 2003;17(12):1847–51.
Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, Mbisa G, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007;196(2):199–207.
Esteban M, Garcia MA, Domingo-Gil E, Arroyo J, Nombela C, Rivas C. The latency protein LANA2 from Kaposi’s sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. J Gen Virol. 2003;84(Pt 6):1463–70.
Fakhari FD, Jeong JH, Kanan Y, Dittmer DP. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest. 2006;116(3):735–42.
Farge D. Kaposi’s sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med. 1993;2(6):339–43.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.
Fernandez L, Serraino D, Rezza G, Lence J, Ortiz RM, Cruz T, et al. Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba. Br J Cancer. 2002;87(11):1253–6.
Ferreira S, Sanabani S, Reis AD, Chamone DF, Sabino EC. Human herpesvirus type 8 among Brazilian blood donors. Transfusion. 2003;43(12):1764–5.
Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci. 2003;116(Pt 18):3721–8.
Fiore JR, Volpe A, Tosatti MA, De Valentin L, Favia A, Chironna M, et al. High seroprevalence of human herpesvirus 8 (HHV-8) in HIV-1-infected pregnant women of Southeastern Italy: association with injection drug use and hepatitis C virus infection. J Med Virol. 2004;72(4):656–60.
Flore O, Rafii S, Ely S, O’Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi’s sarcoma- associated herpesvirus. Nature. 1998;394(6693):588–92.
Foreman KE, Friborg J, Chandran B, Katano H, Sata T, Mercader M, et al. Injection of human herpesvirus-8 in human skin engrafted on SCID mice induces Kaposi’s sarcoma-like lesions. J Dermatol Sci. 2001;26(3):182–93.
Frances C, Mouquet C, Marcelin AG, Barete S, Agher R, Charron D, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation. 2000;69(9):1776–9.
Frances C, Marcelin AG, Legendre C, Chevret S, Dussaix E, Lejeune J, et al. The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant. 2009;9(11):2580–6.
Franceschi S, Geddes M. Epidemiology of classic Kaposi’s sarcoma, with special reference to Mediterranean population. Tumori. 1995;81(5):308–14.
Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M, et al. Kaposi sarcoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99(5):800–4.
Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402(6764):889–94.
Fujii T, Taguchi H, Katano H, Mori S, Nakamura T, Nojiri N, et al. Seroprevalence of human herpesvirus 8 in human immunodeficiency virus 1-positive and human immunodeficiency virus 1-negative populations in Japan. J Med Virol. 1999;57(2):159–62.
Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, Hayward GS, et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi’s sarcoma-associated herpesvirus latency. Nat Med. 2003;9(3):300–6.
Fujiwara S, Nakamura H. Animal models for gammaherpesvirus infections: recent development in the analysis of virus-induced pathogenesis. Pathogens. 2020;9(2)116. https://doi.org/10.3390/pathogens9020116.
Gabaev I, Williamson JC, Crozier TWM, Schulz TF, Lehner PJ. Quantitative proteomics analysis of lytic KSHV infection in human endothelial cells reveals targets of viral immune modulation. Cell Rep. 2020;33(2):108249.
Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi’s sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol. 2005;23(6):1253–60.
Gambus G, Bourboulia D, Esteve A, Lahoz R, Rodriguez C, Bolao F, et al. Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. AIDS. 2001;15(9):1167–74.
Gandy SZ, Linnstaedt SD, Muralidhar S, Cashman KA, Rosenthal LJ, Casey JL. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. J Virol. 2007;81(24):13544–51.
Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest. 2010;120(4):939–49.
Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996a;335(4):233–41.
Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med. 1996b;2(8):925–8.
Garrigues HJ, Rubinchikova YE, Rose TM. KSHV cell attachment sites revealed by ultra sensitive tyramide signal amplification (TSA) localize to membrane microdomains that are up-regulated on mitotic cells. Virology. 2014;452–453:75–85.
Gasperini P, Barbierato M, Martinelli C, Rigotti P, Marchini F, Masserizzi G, et al. Use of a BJAB-derived cell line for isolation of human herpesvirus 8. J Clin Microbiol. 2005;43(6):2866–75.
Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, et al. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res. 2012;72(5):1157–69.
Gaye-Diallo A, Toure AT, Gessain A, Gueye-Ndiaye A, Ndour AN, Toure-Kane NC, et al. Preliminary study of human Herpesvirus type 8 infection in pregnant women in Dakar (Senegal). Bull Soc Pathol Exot. 2001;94(3):231–4.
Geddes M, Franceschi S, Barchielli A, Falcini F, Carli S, Cocconi G, et al. Kaposi’s sarcoma in Italy before and after the AIDS epidemic. Br J Cancer. 1994;69(2):333–6.
Gelgor A, Gam Ze Letova C, Yegorov Y, Kalt I, Sarid R. Nucleolar stress enhances lytic reactivation of the Kaposi’s sarcoma-associated herpesvirus. Oncotarget. 2018;9(17):13822–33.
Gerard L, Berezne A, Galicier L, Meignin V, Obadia M, De Castro N, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB trial. J Clin Oncol. 2007;25(22):3350–6.
Geras-Raaka E, Arvanitakis L, Bais C, Cesarman E, Mesri EA, Gershengorn MC. Inhibition of constitutive signaling of Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor by protein kinases in mammalian cells in culture. J Exp Med. 1998;187(5):801–6.
Gessain A, Mauclere P, van Beveren M, Plancoulaine S, Ayouba A, Essame-Oyono JL, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer. 1999;81(2):189–92.
Giraldo G, Beth E, Haguenau F. Herpes-type virus particles in tissue culture of Kaposi’s sarcoma from different geographic regions. J Natl Cancer Inst. 1972;49(6):1509–26.
Giraldo G, Beth E, Huang ES. Kaposi’s sarcoma and its relationship to cytomegalovirus (CMNV). III. CMV DNA and CMV early antigens in Kaposi’s sarcoma. Int J Cancer. 1980;26(1):23–9.
Gnann JW Jr, Pellett PE, Jaffe HW. Human herpesvirus 8 and Kaposi’s sarcoma in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):S72–S6.
Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood. 2005;105(6):2510–8.
Goedert JJ, Kedes DH, Ganem D. Antibodies to human herpesvirus 8 in women and infants born in Haiti and the USA [letter]. Lancet. 1997;349(9062):1368.
Gong D, Dai X, Jih J, Liu YT, Bi GQ, Sun R, et al. DNA-packing portal and capsid-associated tegument complexes in the tumor herpesvirus KSHV. Cell. 2019;178(6):1329–43 e12.
Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JT, et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature. 2007;450(7172):1096–9.
Graffeo R, Ranno S, Marchetti S, Capodicasa N, Schito AM, Fuga L, et al. HHV 8 seroprevalence and transmission within Albanian family groups. New Microbiol. 2003;26(1):1–6.
Grisotto MG, Garin A, Martin AP, Jensen KK, Chan P, Sealfon SC, et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J Clin Invest. 2006;116(5):1264–73.
Grossman Z, Iscovich J, Schwartz F, Azizi E, Klepfish A, Schattner A, et al. Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc. 2002;77(9):905–9.
Grossmann C, Podgrabinska S, Skobe M, Ganem D. Activation of NF-kappaB by the latent vFLIP gene of Kaposi’s sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J Virol. 2006;80(14):7179–85.
Grulich AE, Beral V, Swerdlow AJ. Kaposi’s sarcoma in England and Wales before the AIDS epidemic. Br J Cancer. 1992;66(6):1135–7.
Grulich AE, Cunningham P, Munier ML, Prestage G, Amin J, Ringland C, et al. Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia. Sex Health. 2005;2(1):13–8.
Grundhoff A, Ganem D. Mechanisms governing expression of the v-FLIP gene of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2001;75(4):1857–63.
Guadalupe M, Pollock BH, Westbrook S, Redding S, Bullock D, Anstead G, et al. Risk factors influencing antibody responses to Kaposi’s sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;56(1):83–90.
Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199(7):993–1003.
Guasparri I, Wu H, Cesarman E. The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep. 2006;7(1):114–9.
Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, Bossi P, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis. 2006;194(8):1078–88.
Guito J, Lukac DM. KSHV Rta promoter specification and viral reactivation. Front Microbiol. 2012;3:30.
Gurtsevich VE, Kadyrova EL, Chernova VA, Demidov LV, Gruzdev BM, Gessain A, et al. Search for HHV-8 associated diseases reservoir and spread paths of HHV-8 in Russia. Vopr Virusol. 2004;49(6):20–4.
Guttman-Yassky E, Bar-Chana M, Yukelson A, Linn S, Friedman-Birnbaum R, Bergman R, et al. Epidemiology of classic Kaposi’s sarcoma in the Israeli Jewish population between 1960 and 1998. Br J Cancer. 2003;89(9):1657–60.
Guttman-Yassky E, Cohen A, Kra-Oz Z, Friedman-Birnbaum R, Sprecher E, Zaltzman N, et al. Familial clustering of classic Kaposi sarcoma. J Infect Dis. 2004;189(11):2023–6.
Guttman-Yassky E, Kra-Oz Z, Dubnov J, Friedman-Birnbaum R, Segal I, Zaltzman N, et al. Infection with Kaposi’s sarcoma-associated herpesvirus among families of patients with classic Kaposi’s sarcoma. Arch Dermatol. 2005;141(11):1429–34.
Guttman-Yassky E, Abada R, Kra-Oz Z, Sattinger J, Perelman A, Bergman R, et al. Relationship between human herpesvirus 8 loads and disease stage in classic Kaposi sarcoma patients. Diagn Microbiol Infect Dis. 2007;57(4):387–92.
Hahn AS, Kaufmann JK, Wies E, Naschberger E, Panteleev-Ivlev J, Schmidt K, et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi’s sarcoma-associated herpesvirus. Nat Med. 2012;18(6):961–6.
Hannachi N, Ben Fredj N, Samoud S, Ferjani A, Khlif A, Boughammoura L, et al. Seroprevalence and risk factors of human herpes virus 8 infection in Central-East Tunisia. Pathol Biol (Paris). 2012;60(5):282–6.
Hansen A, Henderson S, Lagos D, Nikitenko L, Coulter E, Roberts S, et al. KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev. 2010;24(2):195–205.
Harwood AR, Osoba D, Hofstader SL, Goldstein MB, Cardella CJ, Holecek MJ, et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med. 1979;67(5):759–65.
Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest. 2011;121(2):752–68.
Hayward GS, Zong JC. Modern evolutionary history of the human KSHV genome. Curr Top Microbiol Immunol. 2007;312:1–42.
Hjalgrim H, Melbye M, Pukkala E, Langmark F, Frisch M, Dictor M, et al. Epidemiology of Kaposi’s sarcoma in the Nordic countries before the AIDS epidemic. Br J Cancer. 1996;74(9):1499–502.
Hjalgrim H, Lind I, Rostgaard K, Melbye M, Frisch M, Stossel A, et al. Prevalence of human herpesvirus 8 antibodies in young adults in Denmark (1976-1977). J Natl Cancer Inst. 2001;93(20):1569–71.
Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006;355(13):1331–8.
Holst PJ, Rosenkilde MM, Manfra D, Chen SC, Wiekowski MT, Holst B, et al. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J Clin Invest. 2001;108(12):1789–96.
Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet. 2004;36(7):683–5.
Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8. Blood. 1997;90(3):1186–91.
Hu J, Renne R. Characterization of the minimal replicator of Kaposi’s sarcoma-associated herpesvirus latent origin. J Virol. 2005;79(4):2637–42.
Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, et al. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981;2(8247):598–600.
IeDEA AI-dCPWGf, EuroCoord Ci. Comparison of Kaposi sarcoma risk in human immunodeficiency virus-positive adults across 5 continents: a multiregional multicohort study. Clin Infect Dis. 2017;65(8):1316–26.
International Collaboration on HIV, Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92(22):1823–30.
Iscovich J, Boffetta P, Winkelmann R, Brennan P, Azizi E. Classic Kaposi’s sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study. AIDS. 1998;12(15):2067–72.
Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000a;88(3):500–17.
Iscovich J, Fischbein A, Fisher-Fischbein J, Freedman LS, Eng SM, Boffetta P, et al. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus in healthy adults in Israel. Anticancer Res. 2000b;20(3B):2119–22.
Jalilvand S, Shoja Z, Mokhtari-Azad T, Nategh R, Gharehbaghian A. Seroprevalence of human herpesvirus 8 (HHV-8) and incidence of Kaposi’s sarcoma in Iran. Infect Agent Cancer. 2011;6:5.
Jarviluoma A, Ojala PM. Cell signaling pathways engaged by KSHV. Biochim Biophys Acta. 2006;1766(1):140–58.
Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, et al. Usefulness of Kaposi’s sarcoma-associated herpesvirus (KSHV) DNA viral load in whole blood for diagnosis and monitoring of KSHV-associated diseases. J Clin Microbiol. 2018;56(6).
Jary A, Leducq V, Desire N, Petit H, Palich R, Joly V, et al. New Kaposi’s sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. J Infect Dis. 2020;222(8):1320–8.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R, et al. Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A. 2003;100(18):10399–404.
Johnston BP, Pringle ES, McCormick C. KSHV activates unfolded protein response sensors but suppresses downstream transcriptional responses to support lytic replication. PLoS Pathog. 2019;15(12):e1008185. https://doi.org/10.3390/v12010012.
Journo G, Tushinsky C, Shterngas A, Avital N, Eran Y, Karpuj MV, et al. Modulation of cellular CpG DNA methylation by Kaposi’s sarcoma-associated herpesvirus. J Virol. 2018;92(16):e00008–18. https://doi.org/10.1128/JVI.00008-18.
Juhasz A, Remenyik E, Konya J, Veress G, Begany A, Andirko I, et al. Prevalence and age distribution of human herpesvirus-8 specific antibodies in Hungarian blood donors. J Med Virol. 2001;64(4):526–30.
Juillard F, Tan M, Li S, Kaye KM. Kaposi’s sarcoma herpesvirus genome persistence. Front Microbiol. 2016;7:1149.
Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, Matikainen MT, et al. Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998;58(8):1599–604.
Kaasinen E, Aavikko M, Vahteristo P, Patama T, Li Y, Saarinen S, et al. Nationwide registry-based analysis of cancer clustering detects strong familial occurrence of Kaposi sarcoma. PLoS One. 2013;8(1):e55209.
Kaldis P, Ojala PM, Tong L, Makela TP, Solomon MJ. CAK-independent activation of CDK6 by a viral cyclin. Mol Biol Cell. 2001;12(12):3987–99.
Kaleeba JA, Berger EA. Kaposi’s sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT. Science. 2006;311(5769):1921–4.
Kaminer B, Murray JF. Sarcoma idiopathicum multiplex haemorrhagicum of Kaposi, with special reference to its incidence in the South African Negro, and two case reports. S Afr J Clin Sci. 1950;1(1):1–25.
Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi’s sarcoma in Africa. J Gen Virol. 1997;78(Pt 4):847–55.
Kazanji M, Dussart P, Duprez R, Tortevoye P, Pouliquen JF, Vandekerkhove J, et al. Serological and molecular evidence that human herpesvirus 8 is endemic among Amerindians in French Guiana. J Infect Dis. 2005;192(9):1525–9.
Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest. 1997;99(9):2082–6.
Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;2(8):918–24.
Kedes DH, Ganem D, Ameli N, Bacchetti P, Greenblatt R. The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women. JAMA. 1997;277(6):478–81.
Kimball LE, Casper C, Koelle DM, Morrow R, Corey L, Vieira J. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis. 2004;189(11):2016–22.
Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101(10):4115–21.
Koga T, Sumiyoshi R, Kawakami A, Yoshizaki K. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman’s disease. Mod Rheumatol. 2019;29(2):302–5.
Kovaleva M, Bussmeyer I, Rabe B, Grotzinger J, Sudarman E, Eichler J, et al. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol. 2006;80(17):8510–20.
Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, Chandran B. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi’s sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol. 2004;78(7):3601–20.
Krown SE, Lee JY, Dittmer DP, Consortium AM. More on HIV-associated Kaposi’s sarcoma. N Engl J Med. 2008;358(5):535–6. author reply 6
Krown SE, Dittmer DP, Cesarman E. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. J Infect Dis. 2011;203(8):1082–6.
Kumar B, Chandran B. KSHV entry and trafficking in target cells-hijacking of cell signal pathways, actin and membrane dynamics. Viruses. 2016;8(11):305. https://doi.org/10.3390/v8110305.
Kumar B, Roy A, Veettil MV, Chandran B. Insight into the roles of E3 ubiquitin ligase c-Cbl, ESCRT machinery, and host cell signaling in Kaposi’s sarcoma-associated herpesvirus entry and trafficking. J Virol. 2018;92(4):e01376-17. https://doi.org/10.1128/JVI.01376-17.
Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5(5):465–75.
Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog. 2014;10(3):e1004046.
Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, Herndier B, et al. De novo infection and serial transmission of Kaposi’s sarcoma-associated herpesvirus in cultured endothelial cells. J Virol. 2002;76(5):2440–8.
Lallemand F, Desire N, Rozenbaum W, Nicolas JC, Marechal V. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J Clin Microbiol. 2000;38(4):1404–8.
Lampinen TM, Kulasingam S, Min J, Borok M, Gwanzura L, Lamb J, et al. Detection of Kaposi’s sarcoma-associated herpesvirus in oral and genital secretions of Zimbabwean women. J Infect Dis. 2000;181(5):1785–90.
Lan K, Kuppers DA, Verma SC, Robertson ES. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. J Virol. 2004;78(12):6585–94.
Landman R, Karsenty E, Katz L, Saimot AG. Kaposi’s sarcoma in Israel: epidemiologic data, 1960–1980. Bull Soc Pathol Exot Fil. 1984;77(4 Pt 2):572–6.
Laney AS, Dollard SC, Jaffe HW, Offermann MK, Spira TJ, Gunthel CJ, et al. Repeated measures study of human herpesvirus 8 (HHV-8) DNA and antibodies in men seropositive for both HHV-8 and HIV. AIDS. 2004;18(13):1819–26.
Lavreys L, Chohan B, Ashley R, Richardson BA, Corey L, Mandaliya K, et al. Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. J Infect Dis. 2003;187(3):359–63.
Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS. 1998;12(7):F45–F9.
Lee JS, Li Q, Lee JY, Lee SH, Jeong JH, Lee HR, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol. 2009;11(11):1355–62.
Lee HR, Brulois K, Wong L, Jung JU. Modulation of immune system by Kaposi’s sarcoma-associated herpesvirus: lessons from viral evasion strategies. Front Microbiol. 2012;3:44.
Lee AJ, Brenner L, Mourad B, Monteiro C, Vega KJ, Munoz JC. Gastrointestinal Kaposi’s sarcoma: case report and review of the literature. World J Gastrointest Pharmacol Ther. 2015;6(3):89–95.
Lei X, Bai Z, Ye F, Xie J, Kim CG, Huang Y, et al. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat Cell Biol. 2010;12(2):193–9.
Lemma E, Constantine NT, Kassa D, Messele T, Mindaye T, Taye G, et al. Human herpesvirus 8 infection in HIV-1-infected and uninfected pregnant women in Ethiopia. Ethiop Med J. 2009;47(3):205–11.
Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet. 1996;348(9031):858–61.
Letang E, Almeida JM, Miro JM, Ayala E, White IE, Carrilho C, et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in Mozambique: a prospective study. J Acquir Immune Defic Syndr. 2010;53(5):589–97.
Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi’s sarcoma. Eur J Cancer. 2001;37(10):1288–95.
Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F, et al. Kaposi’s sarcoma-associated herpesvirus encodes a functional cyclin. J Virol. 1997;71(3):1984–91.
Liang D, Lin X, Lan K. Looking at Kaposi’s sarcoma-associated herpesvirus-host interactions from a microRNA viewpoint. Front Microbiol. 2011;2:271.
Lieberman PM. Keeping it quiet: chromatin control of gammaherpesvirus latency. Nat Rev Microbiol. 2013;11(12):863–75.
Lisco A, Barbierato M, Fiore JR, Gasperini P, Favia A, Volpe A, et al. Pregnancy and human herpesvirus 8 reactivation in human immunodeficiency virus type 1-infected women. J Clin Microbiol. 2006;44(11):3863–71.
Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, et al. A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis. 2003;187(1):149–53.
Low W, Harries M, Ye H, Du MQ, Boshoff C, Collins M. Internal ribosome entry site regulates translation of Kaposi’s sarcoma-associated herpesvirus FLICE inhibitory protein. J Virol. 2001;75(6):2938–45.
Lubyova B, Pitha PM. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol. 2000;74(17):8194–201.
Lubyova B, Kellum MJ, Frisancho AJ, Pitha PM. Kaposi’s sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. J Biol Chem. 2004;279(9):7643–54.
Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, Trovato R, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med. 2000a;343(19):1378–85.
Luppi M, Barozzi P, Santagostino G, Trovato R, Schulz TF, Marasca R, et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood. 2000b;96(9):3279–81.
Macveigh-Fierro D, Rodriguez W, Miles J, Muller M. Stealing the show: KSHV hijacks host RNA regulatory pathways to promote infection. Viruses. 2020;12(9):1024. https://doi.org/10.3390/v12091024.
Malope BI, Pfeiffer RM, Mbisa G, Stein L, Ratshikhopha EM, O’Connell DL, et al. Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. J Acquir Immune Defic Syndr. 2007;44(3):351–5.
Mancuso R, Biffi R, Valli M, Bellinvia M, Tourlaki A, Ferrucci S, et al. HHV8 a subtype is associated with rapidly evolving classic Kaposi’s sarcoma. J Med Virol. 2008;80(12):2153–60.
Mantina H, Kankasa C, Klaskala W, Brayfield B, Campbell J, Du Q, et al. Vertical transmission of Kaposi’s sarcoma-associated herpesvirus. Int J Cancer. 2001;94(5):749–52.
Marcelin AG, Dupin N, Bossi P, Calvez V. Seroprevalence of human herpesvirus-8 in healthy subjects and patients with AIDS-associated and classical Kaposi’s sarcoma in France [letter]. AIDS. 1998;12(5):539–40.
Marcelin AG, Roque-Afonso AM, Hurtova M, Dupin N, Tulliez M, Sebagh M, et al. Fatal disseminated Kaposi’s sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl. 2004;10(2):295–300.
Marcelin AG, Calvez V, Dussaix E. KSHV after an organ transplant: should we screen? Curr Top Microbiol Immunol. 2007;312:245–62.
Martin JN. Diagnosis and epidemiology of human herpesvirus 8 infection. Semin Hematol. 2003;40(2):133–42.
Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338(14):948–54.
Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, et al. Remission from Kaposi’s sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer. 2006;94(7):1000–6.
Martro E, Esteve A, Schulz TF, Sheldon J, Gambus G, Munoz R, et al. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi’s sarcoma among men who have sex with men in a European multicentre study. Int J Cancer. 2007;120(5):1129–35.
Matondo P. Kaposi’s sarcoma in Africa. Clin Dermatol. 1999;17(2):197–207. discussion 105–6
Matta H, Sun Q, Moses G, Chaudhary PM. Molecular genetic analysis of human herpes virus 8-encoded viral FLICE inhibitory protein-induced NF-kappaB activation. J Biol Chem. 2003;278(52):52406–11.
Matteoli B, Broccolo F, Scaccino A, Cottoni F, Angeloni A, Faggioni A, et al. In vivo and in vitro evidence for an association between the route-specific transmission of HHV-8 and the virus genotype. J Med Virol. 2012;84(5):786–91.
Maurer T, Ponte M, Leslie K. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007;357(13):1352–3.
Mayama S, Cuevas LE, Sheldon J, Omar OH, Smith DH, Okong P, et al. Prevalence and transmission of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer. 1998;77(6):817–20.
Mbulaiteye SM, Pfeiffer RM, Whitby D, Brubaker GR, Shao J, Biggar RJ. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis. 2003a;187(11):1780–5.
Mbulaiteye SM, Biggar RJ, Bakaki PM, Pfeiffer RM, Whitby D, Owor AM, et al. Human herpesvirus 8 infection and transfusion history in children with sickle-cell disease in Uganda. J Natl Cancer Inst. 2003b;95(17):1330–5.
Mbulaiteye SM, Pfeiffer RM, Engels EA, Marshall V, Bakaki PM, Owor AM, et al. Detection of Kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. J Infect Dis. 2004;190(8):1382–6.
Mbulaiteye SM, Biggar RJ, Pfeiffer RM, Bakaki PM, Gamache C, Owor AM, et al. Water, socioeconomic factors, and human herpesvirus 8 infection in Ugandan children and their mothers. J Acquir Immune Defic Syndr. 2005;38(4):474–9.
Mbulaiteye SM, Pfeiffer RM, Dolan B, Tsang VC, Noh J, Mikhail NN, et al. Seroprevalence and risk factors for human herpesvirus 8 infection, rural Egypt. Emerg Infect Dis. 2008;14(4):586–91.
McCarty KA, Bungu Z. Kaposi’s sarcoma in a two week old infant born to a mother with Kaposi’s sarcoma/AIDS. Cent Afr J Med. 1995;41(10):330–1.
McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science. 2005;307(5710):739–41.
Meckes DG Jr, Gunawardena HP, Dekroon RM, Heaton PR, Edwards RH, Ozgur S, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A. 2013;110(31):E2925–33.
Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi’s sarcoma-associated herpesvirus. AIDS. 1997;11(11):1327–32.
Mercader M, Taddeo B, Panella JR, Chandran B, Nickoloff BJ, Foreman KE. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol. 2000;156(6):1961–71.
Meschi S, Schepisi MS, Nicastri E, Bevilacqua N, Castilletti C, Sciarrone MR, et al. The prevalence of antibodies to human herpesvirus 8 and hepatitis B virus in patients in two hospitals in Tanzania. J Med Virol. 2010;82(9):1569–75.
Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707–19.
Miller G, Rigsby MO, Heston L, Grogan E, Sun R, Metroka C, et al. Antibodies to butyrate-inducible antigens of Kaposi’s sarcoma- associated herpesvirus in patients with HIV-1 infection. N Engl J Med. 1996;334(20):1292–7.
Minhas V, Crabtree KL, Chao A, M’Soka TJ, Kankasa C, Bulterys M, et al. Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol. 2008;168(3):311–20.
Miyagi J, Masuda M, Uezato H, Sawada T, Miyakuni T, Miyoshi I, et al. Increased risk of human herpesvirus-8 infection in patients with adult T cell leukemia/lymphoma in Okinawa. Leukemia. 2002;16(9):1881–2.
Mohanna S, Ferrufino JC, Sanchez J, Bravo F, Gotuzzo E. Epidemiological and clinical characteristics of classic Kaposi’s sarcoma in Peru. J Am Acad Dermatol. 2005a;53(3):435–41.
Mohanna S, Maco V, Bravo F, Gotuzzo E. Epidemiology and clinical characteristics of classic Kaposi’s sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease. Int J Infect Dis. 2005b;9(5):239–50.
Mohl BS, Chen J, Longnecker R. Gammaherpesvirus entry and fusion: a tale how two human pathogenic viruses enter their host cells. Adv Virus Res. 2019;104:313–43.
Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 2003;3(1):23–36.
Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332(18):1181–5.
Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, Hoover DR, et al. Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. AIDS. 1996a;10(2):175–80.
Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, et al. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcomae. J Virol. 1996b;70(1):549–58.
Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996c;274(5293):1739–44.
Mseddi M, Abdelmaksoud W, Slah M, Taha JM, Bouassida S, Boudaya S, et al. Kaposi’s sarcoma. A series of 65 cases. Tunis Med. 2005;83(9):528–31.
Mulama DH, Mutsvunguma LZ, Totonchy J, Ye P, Foley J, Escalante GM, et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits. Vaccine. 2019;37(30):4184–94.
Muller A, Bendick C, Salzberger B, Him S, Franzen C. Seroprevalence of human herpesvirus-8 in different patient groups in Cambodia and Germany. Eur J Clin Microbiol Infect Dis. 2001;20(4):291–3.
Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251–61.
Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Azumi N, Kishishita M, et al. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) transforming gene. J Virol. 1998;72(6):4980–8.
Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM, et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi’s sarcoma. Cancer Cell. 2007;11(3):245–58.
Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe. 2009;5(4):376–85.
Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88(2):645–56.
Nakajima KI, Guevara-Plunkett S, Chuang F, Wang KH, Lyu Y, Kumar A, et al. Rainbow Kaposi’s sarcoma-associated herpesvirus revealed heterogenic replication with dynamic gene expression. J Virol. 2020;94(8):e01565-19. https://doi.org/10.1128/JVI.01565-19.
Nakamura S, Salahuddin SZ, Biberfeld P, Ensoli B, Markham PD, Wong-Staal F, et al. Kaposi’s sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science. 1988;242(4877):426–30.
Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. Global changes in Kaposi’s sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol. 2003;77(7):4205–20.
Naranatt PP, Krishnan HH, Smith MS, Chandran B. Kaposi’s sarcoma-associated herpesvirus modulates microtubule dynamics via RhoA-GTP-diaphanous 2 signaling and utilizes the dynein motors to deliver its DNA to the nucleus. J Virol. 2005;79(2):1191–206.
Nascimento MC, de Souza VA, Sumita LM, Freire W, Weiss HA, Sabino EC, et al. Prevalence of, and risk factors for Kaposi’s sarcoma-associated herpesvirus infection among blood donors in Brazil: a multi-center serosurvey. J Med Virol. 2008;80(7):1202–10.
Nascimento MC, Sumita LM, Souza VU, Weiss HA, Oliveira J, Mascheretti M, et al. Seroprevalence of Kaposi sarcoma-associated herpesvirus and other serologic markers in the Brazilian Amazon. Emerg Infect Dis. 2009;15(4):663–7.
Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008;22(8):937–45.
Nuvor SV, Katano H, Ampofo WK, Barnor JS, Sata T. Higher prevalence of antibodies to human herpesvirus 8 in HIV-infected individuals than in the general population in Ghana, West Africa. Eur J Clin Microbiol Infect Dis. 2001;20(5):362–4.
Ojala PM, Sodeik B, Ebersold MW, Kutay U, Helenius A. Herpes simplex virus type 1 entry into host cells: reconstitution of capsid binding and uncoating at the nuclear pore complex in vitro. Mol Cell Biol. 2000a;20(13):4922–31.
Ojala PM, Yamamoto K, Castanos-Velez E, Biberfeld P, Korsmeyer SJ, Makela TP. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol. 2000b;2(11):819–25.
Okroj M, Spiller OB, Korodi Z, Tedeschi R, Dillner J, Blom AM. Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. Vaccine. 2007;25(48):8102–9.
Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96(6):2069–73.
Olsen SJ, Chang Y, Moore PS, Biggar RJ, Melbye M. Increasing Kaposi’s sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi’s sarcoma endemic region, Zambia in 1985. AIDS. 1998;12(14):1921–5.
Operskalski EA, Busch MP, Mosley JW, Kedes DH. Blood donations and viruses. Lancet. 1997;349(9061):1327.
Orzechowska BU, Powers MF, Sprague J, Li H, Yen B, Searles RP, et al. Rhesus macaque rhadinovirus-associated non-Hodgkin lymphoma: animal model for KSHV-associated malignancies. Blood. 2008;112(10):4227–34.
Osmond DH, Buchbinder S, Cheng A, Graves A, Vittinghoff E, Cossen CK, et al. Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA. 2002;287(2):221–5.
Palmieri C, Dhillon T, Thirlwell C, Newsom-Davis T, Young AM, Nelson M, et al. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. HIV Med. 2006;7(5):291–3.
Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, Gao SJ, et al. Risk of Kaposi’s sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi’s sarcoma patients. Blood. 1997;90(7):2826–9.
Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000;156(3):743–9.
Parsons CH, Adang LA, Overdevest J, O’Connor CM, Taylor JR Jr, Camerini D, et al. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest. 2006;116(7):1963–73.
Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med. 2000;343(19):1369–77.
Pei Y, Wong JH, Robertson ES. Herpesvirus epigenetic reprogramming and oncogenesis. Annu Rev Virol. 2020;7(1):309–31.
Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC, Forghani B, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion. 2003;43(9):1260–8.
Penn I. Neoplastic consequences of transplantation and chemotherapy. Cancer Detect Prev Suppl. 1987a;1:149–57.
Penn I. Cancers following cyclosporine therapy. Transplant Proc. 1987b;19(1 Pt 3):2211–3.
Penn I. Sarcomas in organ allograft recipients. Transplantation. 1995;60(12):1485–91.
Perez CL, Tous MI, Zala N, Camino S. Human herpesvirus 8 in healthy blood donors, Argentina. Emerg Infect Dis. 2010;16(1):150–1.
Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grasser FA, et al. Identification of microRNAs of the herpesvirus family. Nat Methods. 2005;2(4):269–76.
Pfeiffer RM, Wheeler WA, Mbisa G, Whitby D, Goedert JJ, de The G, et al. Geographic heterogeneity of prevalence of the human herpesvirus 8 in sub-Saharan Africa: clues about etiology. Ann Epidemiol. 2010;20(12):958–63.
Phillips AM, Jones AG, Osmond DH, Pollack LM, Catania JA, Martin JN. Awareness of Kaposi’s sarcoma-associated herpesvirus among men who have sex with men. Sex Transm Dis. 2008;35(12):1011–4.
Picchio GR, Sabbe RE, Gulizia RJ, McGrath M, Herndier BG, Mosier DE. The KSHV/HHV8-infected BCBL-1 lymphoma line causes tumors in SCID mice but fails to transmit virus to a human peripheral blood mononuclear cell graft. Virology. 1997;238(1):22–9.
Plancoulaine S, Abel L, van Beveren M, Tregouet DA, Joubert M, Tortevoye P, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet. 2000;356(9235):1062–5.
Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.
Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Marshall V, Wang V, et al. Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS). Clin Infect Dis. 2016;62(6):730–8.
Prasad A, Remick J, Zeichner SL. Activation of human herpesvirus replication by apoptosis. J Virol. 2013;87(19):10641–50.
Pringle ES, Wertman J, Melong N, Coombs AJ, Young AL, O’Leary D, et al. The zebrafish xenograft platform-a novel tool for modeling KSHV-associated diseases. Viruses. 2019;12(1).
Punj V, Matta H, Schamus S, Tamewitz A, Anyang B, Chaudhary PM. Kaposi’s sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a. Oncogene. 2010;29(12):1835–44.
Qunibi W, Akhtar M, Sheth K, Ginn HE, Al-Furayh O, DeVol EB, et al. Kaposi’s sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med. 1988;84(2):225–32.
Raab MS, Albrecht JC, Birkmann A, Ya, ubo, lu S, et al. The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open Reading Frame K8.1. J Virol. 1998;72(8):6725–31.
Rabkin CS, Schulz TF, Whitby D, Lennette ET, Magpantay LI, Chatlynne L, et al. Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis. 1998;178(2):304–9.
Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med. 2000;6(10):1121–7.
Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, Stoiber H, et al. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol. 1997;71(8):5915–21.
Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients [see comments]. N Engl J Med. 1998a;339(19):1358–63.
Regamey N, Cathomas G, Schwager M, Wernli M, Harr T, Erb P. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol. 1998b;36(6):1784–6.
Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, et al. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996;2(3):342–6.
Renne R, Dittmer D, Kedes D, Schmidt K, Desrosiers RC, Luciw PA, et al. Experimental transmission of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) to SIV-positive and SIV-negative rhesus macaques. J Med Primatol. 2004;33(1):1–9.
Renwick N, Dukers NH, Weverling GJ, Sheldon JA, Schulz TF, Prins M, et al. Risk factors for human herpesvirus 8 infection in a cohort of drug users in the Netherlands, 1985–1996. J Infect Dis. 2002;185(12):1808–12.
Rezza G, Andreoni M, Dorrucci M, Pezzotti P, Monini P, Zerboni R, et al. Human herpesvirus 8 seropositivity and risk of Kaposi’s sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst. 1999;91(17):1468–74.
Rezza G, Tchangmena OB, Andreoni M, Bugarini R, Toma L, Bakary DK, et al. Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon. Sex Transm Dis. 2000;27(3):159–64.
Rezza G, Danaya RT, Wagner TM, Sarmati L, Owen IL, Monini P, et al. Human herpesvirus-8 and other viral infections, Papua New Guinea. Emerg Infect Dis. 2001;7(5):893–5.
Rinne SJ, Sipila LJ, Sulo P, Jouanguy E, Beziat V, Abel L, et al. Candidate predisposition variants in Kaposi sarcoma as detected by whole-genome sequencing. Open Forum Infect Dis. 2019;6(10):ofz337.
Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi’s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol. 2001;75(1):429–38.
Rose TM, Strand KB, Schultz ER, Schaefer G, Rankin GW Jr, Thouless ME, et al. Identification of two homologs of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species. J Virol. 1997;71(5):4138–44.
Rosen N, Watters AK, Brassard A. Classic Kaposi’s sarcoma in the Inuit of northern Quebec. J Am Acad Dermatol. 2005;52(2 Suppl 1):31–4.
Roshan R, Labo N, Trivett M, Miley W, Marshall V, Coren L, et al. T-cell responses to KSHV infection: a systematic approach. Oncotarget. 2017;8(65):109402–16.
Ross RK, Casagrande JT, Dworsky RL, Levine A, Mack T. Kaposi’s sarcoma in Los Angeles, California. J Natl Cancer Inst. 1985;75(6):1011–5.
Roth WK, Brandstetter H, Sturzl M. Cellular and molecular features of HIV-associated Kaposi’s sarcoma [editorial]. AIDS. 1992;6(9):895–913.
Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A. 1996;93(25):14862–7.
Sadek J, Wuo MG, Rooklin D, Hauenstein A, Hong SH, Gautam A, et al. Modulation of virus-induced NF-kappaB signaling by NEMO coiled coil mimics. Nat Commun. 2020;11(1):1786.
Sadler R, Wu L, Forghani B, Renne R, Zhong W, Herndier B, et al. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi’s sarcoma-associated herpesvirus. J Virol. 1999;73(7):5722–30.
Sallah N, Palser AL, Watson SJ, Labo N, Asiki G, Marshall V, et al. Genome-wide sequence analysis of Kaposi sarcoma-associated herpesvirus shows diversification driven by recombination. J Infect Dis. 2018;218(11):1700–10.
Samols MA, Skalsky RL, Maldonado AM, Riva A, Lopez MC, Baker HV, et al. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog. 2007;3(5):e65.
Santarelli R, De Marco R, Masala MV, Angeloni A, Uccini S, Pacchiarotti R, et al. Direct correlation between human herpesvirus-8 seroprevalence and classic Kaposi’s sarcoma incidence in Northern Sardinia. J Med Virol. 2001;65(2):368–72.
Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest. 2007;117(4):1019–28.
Sarid R, Gao SJ. Viruses and human cancer: from detection to causality. Cancer Lett. 2011;305(2):218–27.
Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998;72(2):1005–12.
Sarid R, Wiezorek JS, Moore PS, Chang Y. Characterization and cell cycle regulation of the major Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter [in process citation]. J Virol. 1999a;73(2):1438–46.
Sarid R, Olsen SJ, Moore PS. Kaposi’s sarcoma-associated herpesvirus epidemiology, virology, and molecular biology. Adv Virus Res. 1999b;52:139–232.
Sarid R, Pizov G, Rubinger D, Backenroth R, Friedlaender MM, Schwartz F, et al. Detection of human herpesvirus-8 DNA in kidney allografts prior to the development of Kaposi’s sarcoma. Clin Infect Dis. 2001;32(10):1502–5.
Sarmati L. HHV-8 infection in African children. Herpesviridae. 2004;11(2):50–3.
Sathish N, Wang X, Yuan Y. Tegument proteins of Kaposi’s sarcoma-associated herpesvirus and related gamma-herpesviruses. Front Microbiol. 2012;3:98.
Schulz TF. Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis. J Antimicrob Chemother. 2000;45(Suppl T3):15–27.
Searles RP, Bergquam EP, Axthelm MK, Wong SW. Sequence and genomic analysis of a rhesus macaque Rhadinovirus with similarity to Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. J Virol. 1999;73(4):3040–53.
Sergerie Y, Abed Y, Roy J, Boivin G. Comparative evaluation of three serological methods for detection of human herpesvirus 8-specific antibodies in Canadian allogeneic stem cell transplant recipients. J Clin Microbiol. 2004;42(6):2663–7.
Serraino D, Franceschi S, Dal Maso L, La Vecchia C. HIV transmission and Kaposi’s sarcoma among European women. AIDS. 1995;9(8):971–3.
Serraino D, Toma L, Andreoni M, Butto S, Tchangmena O, Sarmati L, et al. A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. Eur J Epidemiol. 2001;17(9):871–6.
Shebl FM, Dollard SC, Pfeiffer RM, Biryahwaho B, Amin MM, Munuo SS, et al. Human herpesvirus 8 seropositivity among sexually active adults in Uganda. PLoS One. 2011;6(6):e21286.
Shin HJ, DeCotiis J, Giron M, Palmeri D, Lukac DM. Histone deacetylase classes I and II regulate Kaposi’s sarcoma-associated herpesvirus reactivation. J Virol. 2014;88(2):1281–92.
Si H, Robertson ES. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol. 2006;80(2):697–709.
Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis. 2000;181(2):717–20.
Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaufox MD. Disseminated visceral Kaposi’s sarcoma. Appearance after human renal homograft operation. JAMA. 1969;207(8):1493–6.
Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, et al. Prevalence of Kaposi’s sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996;348(9035):1133–8.
Singh RK, Lamplugh ZL, Lang F, Yuan Y, Lieberman P, You J, et al. KSHV-encoded LANA protects the cellular replication machinery from hypoxia induced degradation. PLoS Pathog. 2019;15(9):e1008025.
Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, Libi F, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi’s sarcoma. Eur J Immunol. 2002;32(10):2711–20.
Sitas F, Newton R. Kaposi’s sarcoma in South Africa. J Natl Cancer Inst Monogr. 2001;28:1–4.
Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, Lopez MC, et al. Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol. 2007;81(23):12836–45.
Smith NA, Sabin CA, Gopal R, Bourboulia D, Labbet W, Boshoff C, et al. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis. 1999;180(3):600–6.
Song J, Ohkura T, Sugimoto M, Mori Y, Inagi R, Yamanishi K, et al. Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line. J Med Virol. 2002;68(3):404–11.
Sosa C, Klaskala W, Chandran B, Soto R, Sieczkowski L, Wu MH, et al. Human herpesvirus 8 as a potential sexually transmitted agent in Honduras. J Infect Dis. 1998;178(2):547–51.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276–80.
Spira TJ, Lam L, Dollard SC, Meng YX, Pau CP, Black JB, et al. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol. 2000;38(6):2174–80.
Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, et al. Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol. 1997;71(1):715–9.
Stebbing J, Gazzard B, Newsom-Davis T, Nelson M, Patterson S, Gotch F, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi’s sarcoma. Int J Cancer. 2004;108(3):473–4.
Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006;367(9521):1495–502.
Stratigos AJ, Malanos D, Touloumi G, Antoniou A, Potouridou I, Polydorou D, et al. Association of clinical progression in classic Kaposi’s sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers. Arch Dermatol. 2005;141(11):1421–6.
Sturzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. Kaposi’s sarcoma-derived cell line SLK is not of endothelial origin, but is a contaminant from a known renal carcinoma cell line. Int J Cancer. 2013;132(8):1954–8.
Suchankova A, Stankova M, Roubalova K, Vandasova J, Bruckova M. Seroprevalence of HHV 8 antibodies among the general population and HIV positive persons in the Czech Republic. J Clin Virol. 2003;28(1):70–6.
Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, Haase A, et al. Kinetics of Kaposi’s sarcoma-associated herpesvirus gene expression. J Virol. 1999;73(3):2232–42.
Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature. 1997;390(6656):184–7.
Szekely L, Chen F, Teramoto N, Ehlin-Henriksson B, Pokrovskaja K, Szeles A, et al. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line. J Gen Virol. 1998;79(Pt 6):1445–52.
Tagawa T, Gao S, Koparde VN, Gonzalez M, Spouge JL, Serquina AP, et al. Discovery of Kaposi’s sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. Proc Natl Acad Sci U S A. 2018;115(50):12805–10.
Tanzi E, Zappa A, Caramaschi F, Amendola A, Lasagna D, Gatti L, et al. Human herpesvirus type 8 infection in an area of northern Italy with high incidence of classical Kaposi’s sarcoma. J Med Virol. 2005;76(4):571–5.
Taylor MM, Chohan B, Lavreys L, Hassan W, Huang ML, Corey L, et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis. 2004;190(3):484–8.
Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi’s sarcoma. J Clin Microbiol. 2001;39(12):4269–73.
Tedeschi R, Bidoli E, Agren A, Hallmans G, Wadell G, De Paoli P, et al. Epidemiology of Kaposi’s sarcoma herpesvirus (HHV8) in Vasterbotten County, Sweden. J Med Virol. 2006;78(3):372–8.
Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997;386(6624):517–21.
Tomkowicz B, Singh SP, Lai D, Singh A, Mahalingham S, Joseph J, et al. Mutational analysis reveals an essential role for the LXXLL motif in the transformation function of the human herpesvirus-8 oncoprotein, kaposin. DNA Cell Biol. 2005;24(1):10–20.
Toptan T, Abere B, Nalesnik MA, Swerdlow SH, Ranganathan S, Lee N, et al. Circular DNA tumor viruses make circular RNAs. Proc Natl Acad Sci U S A. 2018;115(37):E8737–E45.
Toschi E, Sgadari C, Monini P, Barillari G, Bacigalupo I, Palladino C, et al. Treatment of Kaposi’s sarcoma – an update. Anti-Cancer Drugs. 2002;13(10):977–87.
Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, et al. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog. 2010;6(7):e1001013.
Trus BL, Heymann JB, Nealon K, Cheng N, Newcomb WW, Brown JC, et al. Capsid structure of Kaposi’s sarcoma-associated herpesvirus, a gammaherpesvirus, compared to those of an alphaherpesvirus, herpes simplex virus type 1, and a betaherpesvirus, cytomegalovirus. J Virol. 2001;75(6):2879–90.
Tso FY, West JT, Wood C. Reduction of Kaposi’s sarcoma-associated herpesvirus latency using CRISPR-Cas9 to edit the latency-associated nuclear antigen gene. J Virol. 2019;93(7):e02183-18. https://doi.org/10.1128/JVI.02183-18.
Uldrick TS, Wang V, O’Mahony D, Aleman K, Wyvill KM, Marshall V, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis. 2010;51(3):350–8.
Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol. 2019;58(5):538–42.
Varthakavi V, Browning PJ, Spearman P. Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi’s sarcoma-associated herpesvirus. J Virol. 1999;73(12):10329–38.
Verma SC, Lan K, Robertson E. Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol. 2007;312:101–36.
Verschuren EW, Klefstrom J, Evan GI, Jones N. The oncogenic potential of Kaposi’s sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell. 2002;2(3):229–41.
Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 2004;64(2):581–9.
Vieira J, O’Hearn PM. Use of the red fluorescent protein as a marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression. Virology. 2004;325(2):225–40.
Vieira J, Huang ML, Koelle DM, Corey L. Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J Virol. 1997;71(9):7083–7.
Vieira J, O’Hearn P, Kimball L, Chandran B, Corey L. Activation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol. 2001;75(3):1378–86.
Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer. 1993;54(1):26–36.
Walter PR, Philippe E, Nguemby-Mbina C, Chamlian A. Kaposi’s sarcoma: presence of herpes-type virus particles in a tumor specimen. Hum Pathol. 1984;15(12):1145–6.
Wang L, Damania B. Kaposi’s sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res. 2008;68(12):4640–8.
Wang QJ, Jenkins FJ, Jacobson LP, Kingsley LA, Day RD, Zhang ZW, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood. 2001;97(8):2366–73.
Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004;36(7):687–93.
Watanabe T, Sugaya M, Atkins AM, Aquilino EA, Yang A, Borris DL, et al. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol. 2003;77(11):6188–96.
West JT, Wood C. The role of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene. 2003;22(33):5150–63.
Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet. 1995;346(8978):799–802.
Whitby D, Luppi M, Barozzi P, Boshoff C, Weiss RA, Torelli G. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst. 1998;90(5):395–7.
Whitby D, Smith NA, Matthews S, O’Shea S, Sabin CA, Kulasegaram R, et al. Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. J Infect Dis. 1999;179(1):234–6.
Whitby D, Marshall VA, Bagni RK, Miley WJ, McCloud TG, Hines-Boykin R, et al. Reactivation of Kaposi’s sarcoma-associated herpesvirus by natural products from Kaposi’s sarcoma endemic regions. Int J Cancer. 2007;120(2):321–8.
Wies E, Mori Y, Hahn A, Kremmer E, Sturzl M, Fleckenstein B, et al. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008;111(1):320–327.
Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N, et al. Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol. 2002;76(6):2634–40.
Wit FW, Sol CJ, Renwick N, Roos MT, Pals ST, van Leeuwen R, et al. Regression of AIDS-related Kaposi’s sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy [letter]. AIDS. 1998;12(2):218–9.
Wong SW, Bergquam EP, Swanson RM, Lee FW, Shiigi SM, Avery NA, et al. Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi’s sarcoma-associated herpesvirus. J Exp Med. 1999;190(6):827–40.
Wu L, Lo P, Yu X, Stoops JK, Forghani B, Zhou ZH. Three-dimensional structure of the human herpesvirus 8 capsid. J Virol. 2000;74(20):9646–54.
Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi’s sarcoma. J Exp Med. 2000;191(3):445–54.
Ye FC, Zhou FC, Yoo SM, Xie JP, Browning PJ, Gao SJ. Disruption of Kaposi’s sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol. 2004;78(20):11121–9.
Ye F, Zhou F, Bedolla RG, Jones T, Lei X, Kang T, et al. Reactive oxygen species hydrogen peroxide mediates Kaposi’s sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2011;7(5):e1002054.
Yoo J, Kang J, Lee HN, Aguilar B, Kafka D, Lee S, et al. Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi’s sarcoma herpes virus. PLoS Pathog. 2010;6(8):e1001046.
Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity. 2005;22(1):59–70.
Zavitsanou A, Sypsa V, Petrodaskalaki M, Kalapothaki V, Whitby D, Hatzakis A. Human herpesvirus 8 (HHV-8) infection in healthy urban employees from Greece: seroprevalence and associated factors. J Med Virol. 2007;79(5):591–6.
Zhang H, Yang XY, Hong T, Feldman T, Bhattacharyya PK. Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: report of a case in an HIV-positive patient with simultaneous Kaposi sarcoma and a review of the literature. Acta Haematol. 2010;123(4):237–41.
Zhang T, Shao X, Chen Y, Zhang T, Minhas V, Wood C, et al. Human herpesvirus 8 seroprevalence, China. Emerg Infect Dis. 2012;18(1):150–2.
Zheng J, Yang Y, Cui M, Shu ZJ, Han LL, Liu ZQ, et al. Prevalence of Kaposi's sarcoma-associated herpesvirus in Uygur and Han populations from the Urumqi and Kashgar regions of Xinjiang, China. Virol Sin. 2017;32(5):396–403.
Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A. 1996;93(13):6641–6.
Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y. A Kaposi’s sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci U S A. 2002;99(8):5573–8.
Zhu FX, Chong JM, Wu L, Yuan Y. Virion proteins of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2005;79(2):800–11.
Ziegler JL, Katongole-Mbidde E. Kaposi’s sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer. 1996;65(2):200–3.
Ziegler JL, Simonart T, Snoeck R. Kaposi’s sarcoma, oncogenic viruses, and iron. J Clin Virol. 2001;20(3):127–30.
Zoeteweij JP, Moses AV, Rinderknecht AS, Davis DA, Overwijk WW, Yarchoan R, et al. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. Blood. 2001;97(8):2374–80.
Zong JC, Metroka C, Reitz MS, Nicholas J, Hayward GS. Strain variability among Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genomes: evidence that a large cohort of United States AIDS patients may have been infected by a single common isolate. J Virol. 1997;71(3):2505–11.
Zong J, Ciufo DM, Viscidi R, Alagiozoglou L, Tyring S, Rady P, et al. Genotypic analysis at multiple loci across Kaposi’s sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, novel variants and chimerism. J Clin Virol. 2002;23(3):119–48.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Science+Business Media, LLC, part of Springer Nature
About this entry
Cite this entry
Sarid, R., Dünn-Kittenplon, D.(., Calabrò, M.L. (2023). Human Herpesviruses: Kaposi’s Sarcoma and Other Malignancies. In: Kaslow, R.A., Stanberry, L.R., Powers, A.M. (eds) Viral Infections of Humans. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-9544-8_39-2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9544-8_39-2
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-9544-8
Online ISBN: 978-1-4939-9544-8
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Human Herpesviruses: Kaposi’s Sarcoma and Other Malignancies- Published:
- 14 May 2023
DOI: https://doi.org/10.1007/978-1-4939-9544-8_39-2
-
Original
Human Herpesviruses: Kaposi’s Sarcoma and Other Malignancies- Published:
- 15 February 2023
DOI: https://doi.org/10.1007/978-1-4939-9544-8_39-1